August 13, 2025

Ozempic and Vision

Understanding recent updates to the risks associated with semaglutide

The Ophthalmologist

August 12, 2025

Exonate Initiates Phase IIb Trial of EXN407 for Diabetic Eye Disease

EXN407 is the first topical SRPK1 inhibitor to demonstrate safety and efficacy as a monotherapy for non-proliferative diabetic retinopathy (NPDR) and diabetic macular edema

The Ophthalmologist

August 11, 2025

Diet & Sleep Links to Glaucoma

Diet, sleep, and biochemical mediators: novel insights into glaucoma pathogenesis

The Ophthalmologist

August 08, 2025

Also in the News…

The Ophthalmologist brings you the top news stories and studies of the week

The Ophthalmologist

August 08, 2025

Phase III Data on Bausch + Lomb's LUMIFY®

Publication of phase III data on LUMIFY® preservative-free redness reliever eye drops

The Ophthalmologist

August 07, 2025

Glaucoma UK Names 2025 Grant Winners

Three glaucoma projects share a grant total of just under £240,000

The Ophthalmologist

August 06, 2025

SCHWIND PresbyMAX: A Universe of Possibilities

Enhancing outcomes in presbyopic laser vision correction

The Ophthalmologist

August 06, 2025

EyePoint Completes Enrollment of Phase III Trials for DURAVYU

One of the fastest enrolling phase III pivotal programs for wet AMD

The Ophthalmologist

July 30, 2025

MGD Resonations

Quantum molecular resonance introduced as new meibomian gland dysfunction treatment

The Ophthalmologist